RE:RE:RE:RE:RE:Time to Market for H2S PipelineYou are wrong. There's no need to guess. Look at the published data with higher doses.
This is what happens when your mind starts speculating in the wrong direction to a question that has an answer.
GLTA
StockingUp21 wrote: Did the rest of the ppl have 0 LTE Could have been everyone almost else who had 4x LTE they only tell us ones who have 5x and more. If this is what happened everything you say is useless
mstrmnd wrote: H2S is not toxic, review the 2a and 2b datasets.
5/42 people with LTE when 3/42 with LTE were expected on a dose ranging AME study does not equal toxicity. There are numerous variables at play and external factors that cannot be ruled out.
The business strategy is clear, data to support short-term or PRN use is there, why go long-term use for OA given AME findings? That's the whole point of doing the AME! Go for the low-hanging fruit and focus on time-to-market.
4 drugs, IP unified, partnership deals in place, $60M on hand and funded to 2024, best time to acquire Antibe is now, waiting longer is risky since H2S clearly has anti-inflammatory + mucosal healing properties and is worth billions - Bayer may loose out and it could go to Chinese or Korean's.
The public market cap is incorrect and there's a significant mismatch with the true value of this company. Canadian exchanges and day-traders have hurt this company significantly.